|
| Home : Norgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand |
|
Jul 23
2021 |
Norgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand |
|
AMSTERDAM, Netherlands and LOUISVILLE, Ky., July 23, 2021 /PRNewswire/ -- NORGINE B.V. (Norgine) a leading European specialist pharmaceutical company and US WorldMeds (USWM), a Kentucky-based specialty pharmaceutical company, today announced an exclusive licensing agreement by which... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/norgine-bv-and-us-worldmeds-enter-into-exclusive-licensing-agreement-to-commercialise-dfmo-eflornithine-in-europe-commonwealth-of-independent-states-australia-and-new-zealand-301339773.html |
| |
|
Related News
|
» CINDE anuncia que Intel Costa Rica aumentará la inversión a 600 millones de dólares
» Congressman among 10 demonstrators arrested at voting rights protest
|
|
|
